Cart
sales@molnova.com
SU4984
CAS No. 186610-89-9
SU4984( —— )
Catalog No. M23849 CAS No. 186610-89-9
SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 39 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 144 | In Stock |
|
| 100MG | 214 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU4984
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).
-
DescriptionSU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).
-
In VitroSU4984 (5-100 μM; 5 min) inhibits the kinase activity of FGFR1K with an IC50 of 10-20 μM in the presence of 1 mM adenosine triphosphate (ATP).SU4984 (10-90 μM; 5 min) inhibits the autophosphorylation of FGFR1 induced by aFGF in NIH 3T3 cells, with an IC50 of 20-40 μM.SU4984 (5 μM) substantially reduces tyrosine phosphorylation of the wild-type receptor and reduces 50% phosphorylation of constitutive C2 KIT.SU4984 (1-10 μM; 6 days) kills the C2 and P815 cells.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number186610-89-9
-
Formula Weight333.38
-
Molecular FormulaC20H19N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1CN(CCN1C=O)C2=CC=C(C=C2)C=C3C4=CC=CC=C4NC3=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ma Y , Al E . Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells[J]. Journal of Investigative Dermatology, 2000, 114( 2):392-394.
molnova catalog
related products
-
Dovitinib lactate
A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs.
-
Bemarituzumab
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
-
FGFR1/DDR2 inhibitor...
FGFR1/DDR2 inhibitor 1?is an inhibitor of discoindin domain receptor 2 (DDR2) and ?fibroblast growth factor receptor 1 (FGFR1), with IC50 values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.?
